JP2024514339A5 - - Google Patents
Info
- Publication number
- JP2024514339A5 JP2024514339A5 JP2023564025A JP2023564025A JP2024514339A5 JP 2024514339 A5 JP2024514339 A5 JP 2024514339A5 JP 2023564025 A JP2023564025 A JP 2023564025A JP 2023564025 A JP2023564025 A JP 2023564025A JP 2024514339 A5 JP2024514339 A5 JP 2024514339A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- optionally substituted
- membered
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175974P | 2021-04-16 | 2021-04-16 | |
| US63/175,974 | 2021-04-16 | ||
| US202163281493P | 2021-11-19 | 2021-11-19 | |
| US63/281,493 | 2021-11-19 | ||
| PCT/US2022/025083 WO2022221704A1 (en) | 2021-04-16 | 2022-04-15 | Compounds, compositions and methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514339A JP2024514339A (ja) | 2024-04-01 |
| JP2024514339A5 true JP2024514339A5 (cg-RX-API-DMAC7.html) | 2025-04-23 |
Family
ID=81580947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564025A Pending JP2024514339A (ja) | 2021-04-16 | 2022-04-15 | がんを治療する化合物、組成物、及び方法 |
Country Status (14)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4359381A4 (en) * | 2021-06-21 | 2025-04-30 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| US20250042896A1 (en) * | 2021-10-29 | 2025-02-06 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Polycyclic compound as cbl-b inhibitor |
| AU2022379959A1 (en) | 2021-11-05 | 2024-05-09 | Genentech, Inc. | Lactams as cbl-b inhibitors selective over c-cbl |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| US20230414598A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| EP4554570A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent |
| AU2023307165A1 (en) * | 2022-07-12 | 2025-02-06 | Hotspot Therapeutics, Inc. | Methods of preparation of heterocyclic compounds |
| WO2024015863A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
| CA3261875A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR |
| EP4558504A1 (en) * | 2022-07-18 | 2025-05-28 | Insilico Medicine IP Limited | Cbl-b inhibitors and methods of uses thereof |
| WO2024077236A1 (en) * | 2022-10-07 | 2024-04-11 | Hotspot Therapeutics, Inc. | Compounds, compositions and methods of treating disorders |
| WO2024077244A1 (en) * | 2022-10-07 | 2024-04-11 | Hotspot Therapeutics, Inc. | Compounds, compositions and methods of treating disorders |
| WO2024086730A1 (en) * | 2022-10-19 | 2024-04-25 | Hotspot Therapeutics, Inc. | Heterocyclic cbl-b inhibitors for the treatment of cancer |
| WO2024105563A1 (en) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
| WO2024131939A1 (en) * | 2022-12-23 | 2024-06-27 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
| EP4653436A1 (en) * | 2023-01-19 | 2025-11-26 | Guangzhou Yufan Nantu Biotechnologies Co., Ltd | Heterocyclic compounds, preparation method therefor and use thereof |
| CN120530105A (zh) * | 2023-01-20 | 2025-08-22 | 海南先声再明医药股份有限公司 | 取代的三环化合物及其应用 |
| WO2024227436A1 (en) * | 2023-05-04 | 2024-11-07 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2025067342A1 (zh) * | 2023-09-27 | 2025-04-03 | 北京望实智慧科技有限公司 | 用作Cbl-b抑制剂的化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3740837A1 (de) * | 1987-11-27 | 1989-06-08 | Schering Ag | Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel |
| MY150032A (en) * | 2007-07-19 | 2013-11-29 | Merck Sharp & Dohme | Heterocyclic amide compounds as protein kinase inhibitors |
| AU2008317353B2 (en) * | 2007-10-24 | 2014-08-07 | Merck Sharp & Dohme Llc | Heterocycle phenyl amide T-type calcium channel antagonists |
| CA3041650A1 (en) * | 2016-10-27 | 2018-05-03 | Bayer Aktiengesellschaft | 4,5-annulated 1,2,4-triazolones |
| WO2019131575A1 (ja) * | 2017-12-26 | 2019-07-04 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除剤 |
| CA3136348A1 (en) * | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| MX2021015675A (es) * | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| JP2020169215A (ja) * | 2020-07-15 | 2020-10-15 | 住友化学株式会社 | 複素環化合物を用いる有害節足動物防除方法 |
| EP4554570A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent |
| AU2023307165A1 (en) * | 2022-07-12 | 2025-02-06 | Hotspot Therapeutics, Inc. | Methods of preparation of heterocyclic compounds |
| CA3261875A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| WO2024015863A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
-
2022
- 2022-04-15 AU AU2022256514A patent/AU2022256514A1/en active Pending
- 2022-04-15 EP EP22721591.0A patent/EP4323358A1/en active Pending
- 2022-04-15 IL IL307732A patent/IL307732A/en unknown
- 2022-04-15 TW TW111114558A patent/TW202309023A/zh unknown
- 2022-04-15 CA CA3215395A patent/CA3215395A1/en active Pending
- 2022-04-15 JP JP2023564025A patent/JP2024514339A/ja active Pending
- 2022-04-15 MX MX2023012245A patent/MX2023012245A/es unknown
- 2022-04-15 KR KR1020237039416A patent/KR20240037184A/ko active Pending
- 2022-04-15 BR BR112023021068A patent/BR112023021068A2/pt unknown
- 2022-04-15 PE PE2023002860A patent/PE20240767A1/es unknown
- 2022-04-15 US US18/286,966 patent/US20240228482A1/en active Pending
- 2022-04-15 WO PCT/US2022/025083 patent/WO2022221704A1/en not_active Ceased
-
2023
- 2023-10-13 CL CL2023003068A patent/CL2023003068A1/es unknown
- 2023-11-16 CO CONC2023/0015484A patent/CO2023015484A2/es unknown